Cocrystal Pharma announced that its investigational oral protease inhibitor CDI-988 will be presented at the International Society for Antiviral Research Conference in Prague in 2026. The presentation will include Phase 1 clinical data alongside interim results from an ongoing Phase 1b challenge study being conducted at Emory University School of Medicine.
CDI-988 represents the first oral antiviral candidate in development specifically targeting norovirus infections for both prevention and therapeutic use. The advancement is significant given the current lack of approved antiviral treatments or vaccines for norovirus, which remains a substantial public health concern globally. The challenge study format allows researchers to assess the drug's efficacy under controlled conditions with monitored viral exposure.
The conference presentation will provide the investment and medical communities with updated efficacy and safety data as Cocrystal progresses its development program for this indication. The timing of the presentation marks a notable milestone for the company's pipeline in addressing an unmet medical need in viral infectious disease treatment.